The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a Major Problem in...

Sample to Insight

The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a Major Problem in Ovarian Cancer

Prof. Sabine Kasimir-Bauer

Department of Gynecology and Obstetrics

University Hospital Essen

1

Welcome!

Sample to Insight

Legal disclaimer

2

QIAGEN products shown here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention or treatment of a disease.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.QIAGEN.com or can be requested from QIAGEN Technical Services or your local distributor.

Sample to Insight

Agenda

3

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Agenda

4

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Initial situation in ovarian cancer

Classical prognostic factors:• Tumor size

• Grading

• Histological subtype

• Tumor rest after surgery

Sample to Insight

Residual tumor rest after surgery is the only influenceable prognostic factor in ovarian cancer.

Prognostic factors

Sample to Insight

Influence of residual tumor rest after surgery

Sample to Insight

Treatment strategies include:• Primary surgery aiming at macroscopic complete tumor resection

• Subsequent platinum- and paclitaxel-based chemotherapy

• Additional or combined treatment with Avastin (anti-VEGF), Olaparib (PARP inhibitor)

Biggest problem in ovarian cancer: Platinum resistance!

15-20% of patients do not respond to platinum-based chemotherapy which can only be assessed in the follow-up of the disease!

Treatment strategies

Sample to Insight

No suitable marker to predict prognosis and platinum resistance!

Is translational research able tofind predictive markers for:

• Progression-free survival (PFS)

• Overall survival (OS)

• Platinum resistance (PR)

What kind of biomaterial is the bestto look for predictive markers?

• Primary tumor, blood, bone marrow?

• What are the right markers?

Sample to Insight

Primary tumor

Circulating tumor cells in blood (CTCs)

Circulating biomarkers in blood• Circulating tumor DNA

• Circulating microRNAs

• Other

Disseminated tumor cells in the bone Marrow (DTCs)

Biomaterial

Sample to Insight

Do we have reliable methods for selection and detection of DTCs and CTCs?

Are these cells of prognostic significance?

What are the characteristics of these cells?

Important questions to ask

Sample to Insight

Agenda

12

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Agenda

13

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

BM aspiration Density centrifugation,isolation of mononuclear cells

Immunocytochemistry for the detection of cytokeratin-positive cells (DTCs)

ARIOP SL-50 for the evaluation of DTCs

25% Positivity Rate

Selection and detection of DTCs in bone marrow

Sample to Insight

Prognostic relevance of DTCs at primary diagnosis

Sample to Insight

In a multivariate analysis, DTCs were an independent prognostic factor for PFS and OS, but not for PR!

Primary ovarian cancer patients(n = 495)

DTCs in the literature

Sample to Insight

Is the negative prognostic impact of DTCs related to:

• DTC persistence after platinum-based chemotherapy

• to a cellular phenotype, being associated with stem cell character

Negative prognosis impact of DTCs

Sample to Insight

Analysis of BM before and after chemotherapy

Sample to Insight

PFS OS

Analysis of BM before and after chemotherapy (n = 79 patients)

Sample to Insight

Analysis of BM before and after chemotherapy (n = 79 patients)

Sample to Insight

Lin-28 positive / cytokeratin positive BM cells after therapy

Sample to Insight

Comparable results were obtained for the Stem cell marker SOX-2.

Lin-28 positive / cytokeratin negative BM cells after therapy

Sample to Insight

1. DTCs present after therapy express stem cell-associated proteins

2. DTCs with stem cell-associated proteins were also detected (in some cases) after, but not before therapy, which might explain negative outcomes of patients who changed from DTC negative to DTC positive

3. We also detected CK positive / LIN-28 positive (SOX-2 positive) as well as CK negative / LIN-28 positive (SOX-2 positive) cells in all patients

From tumor cells that had undergone epithelial-mesenchymal transition?

Additional therapeutic regimens are necessary to eliminate these cells.

Key messages

Sample to Insight

Agenda

24

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Agenda

25

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

More than 40 different methods for CTC selection are available.

Aside from the prognostic relevance of CTC counts, predictive markers are needed.

Characterization of CTCs is essential to use CTCs as a liquid biopsy for targeted therapy.

Selection and detection of circulating tumor cells (CTCs)

Sample to Insight

Selection / detection methods:

Immunomagnetic cell enrichment • Tumor cell enrichment using magnetic particles

conjugated with an antibodymixture

mRNA isolation and RT • mRNA stabilization, mRNA isolation with oligo(dT)

magnetic beads and cDNA synthesis by reverse transcription

Multiplex PCR • Expression analysis of tumor associate markers

Selection and detection of circulating tumor cells (CTCs)

Sample to Insight

Selection and detection of circulating tumor cells (CTCs)

Sample to Insight

QIAGEN solutions for CTC detection

Sample to Insight

Prognostic significance of CTCs in Ovarian Cancer

Sample to Insight

Aktas et al., Gynecol Oncol, 2011

Prognostic significance of CTCs in ovarian cancer

Using AdnaTest

Sample to Insight

Kuhlmann et al., Clin Cem 2014

N=143 patients

Prognostic significance of CTCs in ovarian cancer

Using AdnaTest OvarianCancer

Sample to Insight

Kuhlmann et al., Clin Cem 2014

Prognostic significance of CTCs in ovarian cancer

Using AdnaTest OvarianCancer

Sample to Insight

We evaluated the prognostic significance of ERCC1-positive CTCs (ERCC1+CTC)

Positive for at least one of the transcripts EpCAM, MUC-1, Ca 12-5.

Positive for ERCC1-transcripts.

ERCC1: excision-repair cross-complementing rodent repair deficiency complementation group 1 nuclease

Hypothesis: Negative prognostic impact of CTCs may arise from a cellular phenotype, being associated with platinum-resistance.

Example experiment

Sample to Insight

Kuhlmann et al., Clin Cem 2014

Prognostic significance of ERCC1+CTCs

Sample to Insight

Kuhlmann et al., Clin Cem 2014

AdnaTest OvarianCancer ERCC1+ predicts platinum failure

Sample to Insight

The presence of ERCC1+CTCs, a potentially platinum-resistant CTC-subgroup, is an independent predictive biomarker for primary platinum-resistance and poor prognosis of ovarian cancer.

Summary

Sample to Insight

How does the additional assessment of ERCC1-transcripts influence overall CTC-detection rate?

Performing paired pre- and post-therapeutic blood analysis, we inquired whether ERCC1+CTC dynamics mirror response to platinum-based chemotherapy.

ERCC1+CTCs as a potential diagnostic tool

ERCC1+CTCs as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.

Sample to Insight

CTC-positive: at least one of the transcripts EpCAM, MUC-1, Ca 12-5 is expressed in the sample (AdnaTest OvarianCancer). ERCC1 was analyzed seperately.

Chebouti et al., 2016 AACR New Orleans

Ovarian cancer patients pre- and post-therapy (n = 65)

Sample to Insight

ERCC1+CTCs

Chebouti et al., 2016 AACR New Orleans

Ovarian cancer patients pre- and post-therapy (n = 65)

Sample to Insight

A

C

B

D

Chebouti et al., 2016 AACR New Orleans

Prognostic significance of CTCs and ERCC1+CTCs

With regard to PFS, OS.

Sample to Insight

Additional assessment of ERCC1-transcripts expands the phenotypic spectrum of CTC-detection and defines an additional highly overlapping fraction of ERCC1-expressing CTCs, which are potentially selected by platinum-based chemotherapy.

We suggest that, beside their capacity to predict platinum-resistance at primary diagnosis, ERCC1+CTCs could additionally be useful as a surrogate for monitoring response to platinum-based chemotherapy and to assess post-therapeutic outcome of ovarian cancer.

Summary

Sample to Insight

Agenda

43

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Agenda

44

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Establish a multimarker genpanel to explore the heterogenousCTC-population in ovarian cancer!

These genes should include:• Epithelial marker

• Stem cell marker

• Marker that indicates epithelial mesenchymal transition (EMT)

Future goals

Recently published, regarding breast cancer:

Sample to Insight

Agenda

46

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight

Agenda

47

Introduction to and overview of ovarian cancer

Disseminating tumor cells (DTCs)

Circulating tumor cells (CTCs)

Future goals

Questions

1

2

3

4

5

Sample to Insight48

Thank you for attending today’s webinar!

Contact QIAGENCall: 1-800-426-8157 (NA)

+49-2103-29-12400 (EU)Email: QIAWebinars@QIAGEN.com

Questions?

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.QIAGEN.com or can be requested from QIAGEN Technical Services or your local distributor.